Human papillomavirus is the most common sexually transmitted viral infection in the world. The infection can cause cancers of the anus, vulva, vagina, penis, and oropharynx. There are more than one hundred subtypes of human papillomavirus, of which thirteen are the high-risk types that may cause cancer. Human papillomavirus 16 and 18 are the main types that are noted as high-risk, causing cancer and neoplasia. Cervical cancer is the fourth most frequent cancer among women worldwide, yet it is preventable and treatable when diagnosed early. Almost all cervical cancer cases are linked to infection with high-risk human papillomavirus subtypes, which are extremely common. Cervical cancer occupies a large place in cancer screening, diagnosis, and treatment. It is critical to include the vaccine in national vaccination programs in order to increase herd immunity to human papillomavirus. The human papillomavirus vaccine should be made accessible to everyone, as well as screening tests for human papillomavirusrelated diseases. The awareness of human papillomavirus vaccines in immunization programs by health authorities can significantly increase the acceptability of the vaccine in communities. As of May 2022, the human papillomavirus vaccine is not included in the national vaccination program in Turkey. In our study, we have compiled why the human papillomavirus vaccine should be included in the vaccination calendar in Turkey, within the scope of the latest research on this subject.
Dergi Türü : Uluslararası
Benzer Makaleler | Yazar | # |
---|
Makale | Yazar | # |
---|